Whitehawk CEO to Discuss ADC Pipeline at Stifel Oncology Forum
Event summary
- Whitehawk Therapeutics CEO Dave Lennon, PhD, to participate in a virtual fireside chat at the 2026 Stifel Virtual Targeted Oncology Forum on May 19, 2026.
- Event scheduled for 3 PM ET, with a replay available for 30 days post-event.
- Whitehawk's ADC portfolio includes three assets in-licensed from WuXi Biologics under an exclusive global commercialization agreement.
The big picture
Whitehawk's participation in the Stifel forum underscores its push to differentiate its ADC portfolio in a competitive oncology market. The company's focus on overcoming first-generation ADC limitations aligns with broader industry trends toward more targeted and efficient cancer therapies. Success will hinge on executing its clinical pipeline and commercializing its assets under the WuXi Biologics agreement.
What we're watching
- Pipeline Progress
- How Whitehawk's ADC portfolio advances through clinical stages will determine its competitive positioning in oncology.
- Commercial Strategy
- Whether the company can leverage its exclusive WuXi Biologics partnership to accelerate global market entry.
- Investor Sentiment
- The pace at which Whitehawk can convert clinical progress into investor confidence amid a crowded ADC landscape.
Related topics